It has been reported that elevated NfL levels and low phospho-tau/tau ratio in the CSF associate with poorer survival and especially with manifestation as motoneuron disease (FTLD-MND), suggesting that these biomarkers may be useful in disease monitoring in FTLD patients (Meeter et al., 2016; Ljubenkov et al., 2018; Meeter L.H.H. et al., 2018). This evidence concerns the gene MAPT and mild neurocognitive disorder.